Abstract Flutamide (250 mg. orally 3 times daily) yielded a subjective response in 5 of 25
fully evaluable patients with hormone-resistant prostatic cancer. Four additional patients had …

Although chronic treatment with luteinizing hormone-releasing hormone agonists achieves
castration levels without side effects other than those related to hypoandrogenism, a …

High-grade prostatic intraepithelial neoplasia (HGPIN) is a precursor to invasive prostate
cancer observed as an isolated entity in a growing subset of men undergoing prostate …

Little is known about the efficacy of flutamide monotherapy in previously untreated patients
with prostatic carcinoma. In this study, 40 patients with advanced disease were treated with …

Synopsis Flutamide is a non-steroidal antiandrogenic drug devoid of hormonal agonist
activity. Flutamide appears to be a specific antiandrogen only at androgen-dependent …

Purpose High-grade prostatic intraepithelial neoplasia (HGPIN) is a potential precursor of
prostate cancer (PCa), and patients with HGPIN are at high risk for PCa development …

METHODS All patients were required to give informed consent prior to participation in this
protocol. Histologic diagnosis of prostate cancer was confinned at our in-stitution before …

ADVANCED PROSTATIC CARCINOMA Flutamide Therapy Afker Conventional Endocrine
Treatment Page 1 ADVANCED PROSTATIC CARCINOMA Flutamide Therapy Afker Conventional …

Prostatic cancer is the second most common malignancy in males and the third leading
cause of cancer deaths in men in the United States. It is estimated that in 1987 there were …

Background: In a recent study by the Casodex Combination Study Group, USA, patients in a
flutamide (750mg/day) plus LH‐RH agonist group showed a high treatment failure rate …